secwatch.observer — SEC 8-K summary
======================================

Issuer:     PROKIDNEY CORP. (PROK)
CIK:        0001850270
Form:       8-K
Filed at:   2023-03-28T23:59:59+00:00
Accession:  0000950170-23-010330
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ProKidney reports Q4 net loss of $24.6M; cash $490.3M; Phase 3 trials advancing
-------------------------------------------------------------------------------

- Cash and cash equivalents $490.3M as of Dec 31, 2022, vs $20.6M year-end 2021.
- R&D expense $20.9M in Q4 2022, up from $10.7M in Q4 2021 due to clinical trial costs and hiring.
- Net loss before noncontrolling interest $24.6M for Q4 2022, compared to $13.7M for Q4 2021.
- Proact1 Phase 3 trial enrolling; interim data expected end of 2024; proact2 trial progressing toward initiation.
- REACT received RMAT designation; EMA provided favorable scientific advice for Phase 3 program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1850270/000095017023010330/0000950170-23-010330-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1850270/000095017023010330/prok-20230328.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-010330

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer